CAR-modified T-cell therapy for cancer: an updated review
Source abstract
Abstract
The use of chimeric antigen receptor (CAR)-modified T cells is a promising approach for cancer immunotherapy. These genetically modified receptors contain an antigen-binding moiety, a hinge region, a transmembrane domain, and an intracellular costimulatory domain resulting in T-cell activation subsequent to antigen binding. Optimal tumor removal through CAR-modified T cells requires suitable target antigen selection, co-stimulatory signaling domain, and the ability of CAR T cells to traffic, persist, and retain antitumor function after adoptive transfer. There are several elements which can improve antitumor function of CAR T cells, including signaling, conditioning chemotherapy and irradiation, tumor burden of the disease, T-cell phenotype, and supplementary cytokine usage. This review outlines four generations of CAR. The pre-clinical and clinical studies showed that this technique has a great potential for treatment of solid and hematological malignancies. The main purpose of the current review is to focus on the pre-clinical and clinical developments of CAR-based immunotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: CAR-T cell therapy research · Nanowire Synthesis and Applications · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Department of Microbiology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
References (100+)
Show source-provided references
1. 10.1016/j.febslet.2013.11.03010.1016/j.febslet.2013.11.030 ↗
2. 10.1097/00002371-200011000-0000410.1097/00002371-200011000-00004 ↗
3. 10.1182/blood.V99.9.317910.1182/blood.V99.9.3179 ↗
4. 10.1007/s00262-010-0842-010.1007/s00262-010-0842-0 ↗
5. 10.1177/10732748130200010810.1177/107327481302000108 ↗
6. 10.1182/blood-2011-04-34854010.1182/blood-2011-04-348540 ↗
7. 10.1158/1078-0432.CCR-07-067410.1158/1078-0432.CCR-07-0674 ↗
8. 10.1073/pnas.96.1.18510.1073/pnas.96.1.185 ↗
9. 10.1182/blood.V96.5.199910.1182/blood.V96.5.1999 ↗
10. 10.1016/j.jaci.2013.01.04910.1016/j.jaci.2013.01.049 ↗
11. 10.1073/pnas.081310110610.1073/pnas.0813101106 ↗
12. 10.1016/S0952-7915(97)80087-810.1016/S0952-7915(97)80087-8 ↗
13. 10.1080/1465324070165607910.1080/14653240701656079 ↗
14. 10.1158/1078-0432.CCR-10-019210.1158/1078-0432.CCR-10-0192 ↗
15. 10.1038/nri134910.1038/nri1349 ↗
16. 10.1038/nri340510.1038/nri3405 ↗
17. 10.1158/0008-5472.CAN-11-010310.1158/0008-5472.CAN-11-0103 ↗
18. 10.1038/leu.2013.27910.1038/leu.2013.279 ↗
19. 10.1016/j.it.2005.03.01010.1016/j.it.2005.03.010 ↗
20. 10.1038/nm109310.1038/nm1093 ↗
21. Darcy PK · Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol · 1998 · 28 · 1663
22. 10.1182/blood-2009-03-20965010.1182/blood-2009-03-209650 ↗
23. 10.1038/mi.2010.910.1038/mi.2010.9 ↗
24. 10.1073/pnas.90.2.72010.1073/pnas.90.2.720 ↗
25. 10.4161/hv.2614710.4161/hv.26147 ↗
26. 10.4049/jimmunol.172.1.10410.4049/jimmunol.172.1.104 ↗
27. 10.1084/jem.2005073210.1084/jem.20050732 ↗
28. 10.1182/blood-2013-09-52953710.1182/blood-2013-09-529537 ↗
29. 10.1158/0008-5472.CAN-07-500610.1158/0008-5472.CAN-07-5006 ↗
30. 10.1038/sj.neo.790001810.1038/sj.neo.7900018 ↗
31. 10.1038/nri70410.1038/nri704 ↗
32. 10.1038/mtna.2013.3210.1038/mtna.2013.32 ↗
33. 10.1073/pnas.86.24.1002410.1073/pnas.86.24.10024 ↗
34. 10.1038/356607a010.1038/356607a0 ↗
35. 10.4049/jimmunol.166.1.18210.4049/jimmunol.166.1.182 ↗
36. 10.4049/jimmunol.169.10.578010.4049/jimmunol.169.10.5780 ↗
37. 10.1038/sj.gt.330202310.1038/sj.gt.3302023 ↗
38. 10.1097/CJI.0b013e318194a6e810.1097/CJI.0b013e318194a6e8 ↗
39. 10.1053/gast.1997.v113.pm932251110.1053/gast.1997.v113.pm9322511 ↗
40. 10.1002/1097-0215(20001001)88:1<115::AID-IJC18>3.0.CO;2-E10.1002/1097-0215(20001001)88:1<115::AID-IJC18>3.0.CO;2-E ↗
41. Hombach A · Cancer Res · 2001 · 61 · 1976
42. 10.4049/jimmunol.167.11.612310.4049/jimmunol.167.11.6123 ↗
43. Hosseini M · Artif Cells Nanomed Biotechnol · 2015 · 1
44. Hu Z · J Immunol · 2013 · 190 · 177
45. 10.1158/1078-0432.CCR-13-033010.1158/1078-0432.CCR-13-0330 ↗
46. 10.1182/blood-2010-05-28330910.1182/blood-2010-05-283309 ↗
47. 10.1084/jem.178.1.36110.1084/jem.178.1.361 ↗
48. 10.1182/blood-2011-09-37613710.1182/blood-2011-09-376137 ↗
49. 10.1016/j.immuni.2009.11.00710.1016/j.immuni.2009.11.007 ↗
50. 10.1371/journal.pone.005783810.1371/journal.pone.0057838 ↗
51. 10.1016/j.bbmt.2010.03.01410.1016/j.bbmt.2010.03.014 ↗
52. 10.1172/JCI3244610.1172/JCI32446 ↗
53. 10.1158/0008-5472.CAN-04-045410.1158/0008-5472.CAN-04-0454 ↗
54. 10.1038/bjc.2012.5710.1038/bjc.2012.57 ↗
55. 10.1126/scitranslmed.300284210.1126/scitranslmed.3002842 ↗
56. Katz SC · Clin Cancer Res · 2015 · 1421 · 2014
57. Kazemi T · Artif Cells Nanomed Biotechnol · 2015 · 1
58. 10.1172/JCI5881410.1172/JCI58814 ↗
59. 10.1158/0008-5472.CAN-10-073510.1158/0008-5472.CAN-10-0735 ↗
60. 10.1089/1043034026035537410.1089/10430340260355374 ↗
61. 10.1158/1078-0432.CCR-06-118310.1158/1078-0432.CCR-06-1183 ↗
62. 10.1182/blood-2011-10-38438810.1182/blood-2011-10-384388 ↗
63. 10.1200/JCO.2014.56.202510.1200/JCO.2014.56.2025 ↗
64. 10.1097/CJI.0b013e3181ac613810.1097/CJI.0b013e3181ac6138 ↗
65. 10.1182/blood-2010-04-28193110.1182/blood-2010-04-281931 ↗
66. 10.1158/0008-5472.CAN-06-209810.1158/0008-5472.CAN-06-2098 ↗
67. 10.4161/2162402X.2014.99444610.4161/2162402X.2014.994446 ↗
68. 10.1158/0008-5472.CAN-06-016010.1158/0008-5472.CAN-06-0160 ↗
69. 10.4161/onci.1885110.4161/onci.18851 ↗
70. 10.1002/eji.20134381210.1002/eji.201343812 ↗
71. 10.1002/ijc.291060040510.1002/ijc.2910600405 ↗
72. 10.1200/JCO.2006.05.996410.1200/JCO.2006.05.9964 ↗
73. 10.1182/blood-2010-07-29452010.1182/blood-2010-07-294520 ↗
74. 10.1158/0008-5472.CAN-10-055210.1158/0008-5472.CAN-10-0552 ↗
75. 10.1146/annurev.immunol.14.1.23310.1146/annurev.immunol.14.1.233 ↗
76. 10.1038/sj.leu.240436610.1038/sj.leu.2404366 ↗
77. 10.1182/blood-2011-05-35444910.1182/blood-2011-05-354449 ↗
78. 10.1038/nbt0102-7010.1038/nbt0102-70 ↗
79. Mezzanzanica D · Cancer Gene Ther · 1997 · 5 · 401
80. 10.1097/CJI.0b013e318282990310.1097/CJI.0b013e3182829903 ↗
81. 10.1038/mt.2010.2410.1038/mt.2010.24 ↗
82. 10.1038/sj.cgt.770010010.1038/sj.cgt.7700100 ↗
83. 10.1038/ncponc066610.1038/ncponc0666 ↗
84. 10.1038/sj.cgt.770103410.1038/sj.cgt.7701034 ↗
85. 10.4049/jimmunol.120308210.4049/jimmunol.1203082 ↗
86. 10.1073/pnas.09256239910.1073/pnas.092562399 ↗
87. 10.1038/sj.cgt.770099310.1038/sj.cgt.7700993 ↗
88. 10.1007/s10875-011-9532-810.1007/s10875-011-9532-8 ↗
89. 10.1038/sj.mt.630010410.1038/sj.mt.6300104 ↗
90. 10.1182/blood-2011-12-40004410.1182/blood-2011-12-400044 ↗
91. 10.1016/j.autrev.2005.04.00410.1016/j.autrev.2005.04.004 ↗
92. Pinthus JH · Cancer Res · 2003 · 63 · 2470
93. 10.1056/NEJMoa110384910.1056/NEJMoa1103849 ↗
94. 10.4161/bioe.2466610.4161/bioe.24666 ↗
95. 10.1081/IMM-20006764610.1081/IMM-200067646 ↗
96. 10.1038/nm.188210.1038/nm.1882 ↗
97. 10.1016/j.ymthe.2005.04.01610.1016/j.ymthe.2005.04.016 ↗
98. 10.1146/annurev.immunol.25.022106.14160910.1146/annurev.immunol.25.022106.141609 ↗
99. 10.4049/jimmunol.173.12.712510.4049/jimmunol.173.12.7125 ↗
100. 10.1016/j.coi.2009.03.00210.1016/j.coi.2009.03.002 ↗